Skip to main content
Top
Published in: Neurotherapeutics 1/2013

01-01-2013 | Original Article

Neuroprotective and Anti-inflammatory Properties of a Coffee Component in the MPTP Model of Parkinson’s Disease

Authors: Kang-Woo Lee, Joo-Young Im, Jong-Min Woo, Hilary Grosso, Yoon-Seong Kim, Ana Clara Cristovao, Patricia K. Sonsalla, David S. Schuster, Marla M. Jalbut, Jose R. Fernandez, Michael Voronkov, Eunsung Junn, Steven P. Braithwaite, Jeffry B. Stock, M. Maral Mouradian

Published in: Neurotherapeutics | Issue 1/2013

Login to get access

Abstract

Consumption of coffee is associated with reduced risk of Parkinson’s disease (PD), an effect that has largely been attributed to caffeine. However, coffee contains numerous components that may also be neuroprotective. One of these compounds is eicosanoyl-5-hydroxytryptamide (EHT), which ameliorates the phenotype of α-synuclein transgenic mice associated with decreased protein aggregation and phosphorylation, improved neuronal integrity and reduced neuroinflammation. Here, we sought to investigate if EHT has an effect in the MPTP model of PD. Mice fed a diet containing EHT for four weeks exhibited dose-dependent preservation of nigral dopaminergic neurons following MPTP challenge compared to animals given control feed. Reductions in striatal dopamine and tyrosine hydroxylase content were also less pronounced with EHT treatment. The neuroinflammatory response to MPTP was markedly attenuated, and indices of oxidative stress and JNK activation were significantly prevented with EHT. In cultured primary microglia and astrocytes, EHT had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced NFκB activation, iNOS induction, and nitric oxide production. EHT also exhibited a robust anti-oxidant activity in vitro. Additionally, in SH-SY5Y cells, MPP+-induced demethylation of phosphoprotein phosphatase 2A (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT. These findings indicate that the neuroprotective effect of EHT against MPTP is through several mechanisms including its anti-inflammatory and antioxidant activities as well as its ability to modulate the methylation and hence activity of PP2A. Our data, therefore, reveal a strong beneficial effect of a novel component of coffee in multiple endpoints relevant to PD.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003;53 Suppl 3:S26–36; discussion S36–28.PubMedCrossRef Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003;53 Suppl 3:S26–36; discussion S36–28.PubMedCrossRef
2.
go back to reference Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009;8:382–397.PubMedCrossRef Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009;8:382–397.PubMedCrossRef
3.
go back to reference Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol 2010;6:193–201.PubMedCrossRef Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol 2010;6:193–201.PubMedCrossRef
4.
go back to reference Parker WD, Jr., Swerdlow RH. Mitochondrial dysfunction in idiopathic Parkinson disease. Am J Hum Genet 1998;62:758–762.PubMedCrossRef Parker WD, Jr., Swerdlow RH. Mitochondrial dysfunction in idiopathic Parkinson disease. Am J Hum Genet 1998;62:758–762.PubMedCrossRef
5.
go back to reference Przedborski S, Jackson-Lewis V. Mechanisms of MPTP toxicity. Mov Disord 1998;13 Suppl 1:35–38.PubMed Przedborski S, Jackson-Lewis V. Mechanisms of MPTP toxicity. Mov Disord 1998;13 Suppl 1:35–38.PubMed
6.
go back to reference Lee KW, Chen W, Junn E, et al. Enhanced phosphatase activity attenuates alpha-Synucleinopathy in a mouse model. J Neurosci 2011;31:6963–6971.PubMedCrossRef Lee KW, Chen W, Junn E, et al. Enhanced phosphatase activity attenuates alpha-Synucleinopathy in a mouse model. J Neurosci 2011;31:6963–6971.PubMedCrossRef
7.
go back to reference Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000;283:2674–2679.PubMedCrossRef Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000;283:2674–2679.PubMedCrossRef
8.
go back to reference Ascherio A, Zhang SM, Hernan MA, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 2001;50:56–63.PubMedCrossRef Ascherio A, Zhang SM, Hernan MA, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 2001;50:56–63.PubMedCrossRef
9.
go back to reference Ascherio A, Weisskopf MG, O'Reilly EJ, et al. Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. Am J Epidemiol 2004;160:977–984.PubMedCrossRef Ascherio A, Weisskopf MG, O'Reilly EJ, et al. Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. Am J Epidemiol 2004;160:977–984.PubMedCrossRef
10.
go back to reference Costa J, Lunet N, Santos C, Santos J, Vaz-Carneiro A. Caffeine exposure and the risk of Parkinson's disease: a systematic review and meta-analysis of observational studies. J Alzheimers Dis 2010;20 Suppl 1:S221–238.PubMed Costa J, Lunet N, Santos C, Santos J, Vaz-Carneiro A. Caffeine exposure and the risk of Parkinson's disease: a systematic review and meta-analysis of observational studies. J Alzheimers Dis 2010;20 Suppl 1:S221–238.PubMed
11.
go back to reference Freeman ND, Park Y, Abnet CC, Hollenbeck AR, Sinha R. Association of coffee drinking with total and cause-specific mortality. N Engl J Med 2012;366:1891–1904.CrossRef Freeman ND, Park Y, Abnet CC, Hollenbeck AR, Sinha R. Association of coffee drinking with total and cause-specific mortality. N Engl J Med 2012;366:1891–1904.CrossRef
12.
go back to reference Trinh K, Andrews L, Krause J, et al. Decaffeinated coffee and nicotine-free tobacco provide neuroprotection in Drosophila models of Parkinson's disease through an NRF2-dependent mechanism. J Neurosci 2010;30:5525–5532.PubMedCrossRef Trinh K, Andrews L, Krause J, et al. Decaffeinated coffee and nicotine-free tobacco provide neuroprotection in Drosophila models of Parkinson's disease through an NRF2-dependent mechanism. J Neurosci 2010;30:5525–5532.PubMedCrossRef
13.
go back to reference Lee KW, Zhao X, Im JY, et al. Apoptosis signal-regulating kinase 1 mediates MPTP toxicity and regulates glial activation. PLoS One 2012;7:e29935.PubMedCrossRef Lee KW, Zhao X, Im JY, et al. Apoptosis signal-regulating kinase 1 mediates MPTP toxicity and regulates glial activation. PLoS One 2012;7:e29935.PubMedCrossRef
14.
go back to reference West MJ, Slomianka L, Gundersen HJ. Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat Rec 1991;231:482–497.PubMedCrossRef West MJ, Slomianka L, Gundersen HJ. Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat Rec 1991;231:482–497.PubMedCrossRef
15.
go back to reference Sonsalla PK, Youngster SK, Kindt MV, Heikkila RE. Characteristics of 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the mouse. J Pharmacol Exp Ther 1987;242:850–857.PubMed Sonsalla PK, Youngster SK, Kindt MV, Heikkila RE. Characteristics of 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the mouse. J Pharmacol Exp Ther 1987;242:850–857.PubMed
16.
go back to reference Alfinito PD, Wang SP, Manzino L, et al. Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. J Neurosci 2003;23:10982–10987.PubMed Alfinito PD, Wang SP, Manzino L, et al. Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. J Neurosci 2003;23:10982–10987.PubMed
17.
go back to reference Kim D, Joe CO, Han PL. Extracellular and intracellular glutathione protects astrocytes from Zn2 + −induced cell death. Neuroreport 2003;14:187–190.PubMedCrossRef Kim D, Joe CO, Han PL. Extracellular and intracellular glutathione protects astrocytes from Zn2 + −induced cell death. Neuroreport 2003;14:187–190.PubMedCrossRef
18.
go back to reference Lee EJ, Woo MS, Moon PG, et al. Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J Immunol 2010;185:615–623.PubMedCrossRef Lee EJ, Woo MS, Moon PG, et al. Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J Immunol 2010;185:615–623.PubMedCrossRef
19.
go back to reference Liberatore GT, Jackson-Lewis V, Vukosavic S, et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999;5:1403–1409.PubMedCrossRef Liberatore GT, Jackson-Lewis V, Vukosavic S, et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999;5:1403–1409.PubMedCrossRef
20.
go back to reference Wu DC, Jackson-Lewis V, Vila M, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002;22:1763–1771.PubMed Wu DC, Jackson-Lewis V, Vila M, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002;22:1763–1771.PubMed
21.
go back to reference Vila M, Jackson-Lewis V, Guegan C, et al. The role of glial cells in Parkinson's disease. Curr Opin Neurol 2001;14:483–489.PubMedCrossRef Vila M, Jackson-Lewis V, Guegan C, et al. The role of glial cells in Parkinson's disease. Curr Opin Neurol 2001;14:483–489.PubMedCrossRef
22.
go back to reference Zolnierowicz S. Type 2A protein phosphatase, the complex regulator of numerous signaling pathways. Biochem Pharmacol 2000;60:1225–1235.PubMedCrossRef Zolnierowicz S. Type 2A protein phosphatase, the complex regulator of numerous signaling pathways. Biochem Pharmacol 2000;60:1225–1235.PubMedCrossRef
23.
go back to reference Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 2001;353:417–439.PubMedCrossRef Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 2001;353:417–439.PubMedCrossRef
24.
go back to reference Garcia A, Cayla X, Guergnon J, et al. Serine/threonine protein phosphatases PP1 and PP2A are key players in apoptosis. Biochimie 2003;85:721–726.PubMedCrossRef Garcia A, Cayla X, Guergnon J, et al. Serine/threonine protein phosphatases PP1 and PP2A are key players in apoptosis. Biochimie 2003;85:721–726.PubMedCrossRef
25.
go back to reference Virshup DM, Shenolikar S. From promiscuity to precision: protein phosphatases get a makeover. Mol Cell 2009;33:537–545.PubMedCrossRef Virshup DM, Shenolikar S. From promiscuity to precision: protein phosphatases get a makeover. Mol Cell 2009;33:537–545.PubMedCrossRef
26.
go back to reference Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007;8:57–69.PubMedCrossRef Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007;8:57–69.PubMedCrossRef
27.
go back to reference Przedborski S, Tieu K, Perier C, Vila M. MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J Bioenerg Biomembr 2004;36:375–379.PubMedCrossRef Przedborski S, Tieu K, Perier C, Vila M. MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J Bioenerg Biomembr 2004;36:375–379.PubMedCrossRef
28.
go back to reference Przedborski S, Ischiropoulos H. Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson's disease. Antioxid Redox Signal 2005;7:685–693.PubMedCrossRef Przedborski S, Ischiropoulos H. Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson's disease. Antioxid Redox Signal 2005;7:685–693.PubMedCrossRef
29.
go back to reference Cassarino DS, Fall CP, Swerdlow RH, et al. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim Biophys Acta 1997;1362:77–86.PubMedCrossRef Cassarino DS, Fall CP, Swerdlow RH, et al. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim Biophys Acta 1997;1362:77–86.PubMedCrossRef
30.
go back to reference Hsu LJ, Sagara Y, Arroyo A, et al. Alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 2000;157:401–410.PubMedCrossRef Hsu LJ, Sagara Y, Arroyo A, et al. Alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 2000;157:401–410.PubMedCrossRef
31.
go back to reference Junn E, Mouradian MM. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci Lett 2002;320:146–150.PubMedCrossRef Junn E, Mouradian MM. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci Lett 2002;320:146–150.PubMedCrossRef
32.
go back to reference Whisler RL, Goyette MA, Grants IS, Newhouse YG. Sublethal levels of oxidant stress stimulate multiple serine/threonine kinases and suppress protein phosphatases in Jurkat T cells. Arch Biochem Biophys 1995;319:23–35.PubMedCrossRef Whisler RL, Goyette MA, Grants IS, Newhouse YG. Sublethal levels of oxidant stress stimulate multiple serine/threonine kinases and suppress protein phosphatases in Jurkat T cells. Arch Biochem Biophys 1995;319:23–35.PubMedCrossRef
33.
go back to reference Rao RK, Clayton LW. Regulation of protein phosphatase 2A by hydrogen peroxide and glutathionylation. Biochem Biophys Res Commun 2002;293:610–616.PubMedCrossRef Rao RK, Clayton LW. Regulation of protein phosphatase 2A by hydrogen peroxide and glutathionylation. Biochem Biophys Res Commun 2002;293:610–616.PubMedCrossRef
34.
go back to reference Kim HS, Song MC, Kwak IH, Park TJ, Lim IK. Constitutive induction of p-Erk1/2 accompanied by reduced activities of protein phosphatases 1 and 2A and MKP3 due to reactive oxygen species during cellular senescence. J Biol Chem 2003;278:37497–37510.PubMedCrossRef Kim HS, Song MC, Kwak IH, Park TJ, Lim IK. Constitutive induction of p-Erk1/2 accompanied by reduced activities of protein phosphatases 1 and 2A and MKP3 due to reactive oxygen species during cellular senescence. J Biol Chem 2003;278:37497–37510.PubMedCrossRef
35.
go back to reference Su B, Wang X, Lee HG, et al. Chronic oxidative stress causes increased tau phosphorylation in M17 neuroblastoma cells. Neurosci Lett 2010;468:267–271.PubMedCrossRef Su B, Wang X, Lee HG, et al. Chronic oxidative stress causes increased tau phosphorylation in M17 neuroblastoma cells. Neurosci Lett 2010;468:267–271.PubMedCrossRef
36.
go back to reference Shanley TP, Vasi N, Denenberg A, Wong HR. The serine/threonine phosphatase, PP2A: endogenous regulator of inflammatory cell signaling. J Immunol 2001;166:966–972.PubMed Shanley TP, Vasi N, Denenberg A, Wong HR. The serine/threonine phosphatase, PP2A: endogenous regulator of inflammatory cell signaling. J Immunol 2001;166:966–972.PubMed
37.
go back to reference Peng X, Tehranian R, Dietrich P, Stefanis L, Perez RG. Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. J Cell Sci 2005;118:3523–3530.PubMedCrossRef Peng X, Tehranian R, Dietrich P, Stefanis L, Perez RG. Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. J Cell Sci 2005;118:3523–3530.PubMedCrossRef
38.
go back to reference Lou H, Montoya SE, Alerte TN, et al. Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo. J Biol Chem 2010;285:17648–17661.PubMedCrossRef Lou H, Montoya SE, Alerte TN, et al. Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo. J Biol Chem 2010;285:17648–17661.PubMedCrossRef
39.
go back to reference Sontag E, Hladik C, Montgomery L, et al. Downregulation of protein phosphatase 2A carboxyl methylation and methyltransferase may contribute to Alzheimer disease pathogenesis. J Neuropathol Exp Neurol 2004;63:1080–1091.PubMed Sontag E, Hladik C, Montgomery L, et al. Downregulation of protein phosphatase 2A carboxyl methylation and methyltransferase may contribute to Alzheimer disease pathogenesis. J Neuropathol Exp Neurol 2004;63:1080–1091.PubMed
40.
go back to reference Eskelinen MH, Kivipelto M. Caffeine as a protective factor in dementia and Alzheimer's disease. J Alzheimers Dis 2010;20 Suppl 1:S167–174.PubMed Eskelinen MH, Kivipelto M. Caffeine as a protective factor in dementia and Alzheimer's disease. J Alzheimers Dis 2010;20 Suppl 1:S167–174.PubMed
41.
go back to reference Voronkov M, Braithwaite SP, Stock JB. Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer's disease. Future Med Chem 2011;3:821–833.PubMedCrossRef Voronkov M, Braithwaite SP, Stock JB. Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer's disease. Future Med Chem 2011;3:821–833.PubMedCrossRef
42.
go back to reference Braithwaite SP, Voronkov M, Stock JB, Mouradian MM. Targeting phosphatases as the next generation of disease modifying therapeutics for Parkinson's disease. Neurochem Int 2012;61(6):899–906.PubMedCrossRef Braithwaite SP, Voronkov M, Stock JB, Mouradian MM. Targeting phosphatases as the next generation of disease modifying therapeutics for Parkinson's disease. Neurochem Int 2012;61(6):899–906.PubMedCrossRef
43.
go back to reference Chen JF, Xu K, Petzer JP, et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 2001;21:RC143.PubMed Chen JF, Xu K, Petzer JP, et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 2001;21:RC143.PubMed
44.
go back to reference Simon DK, Swearingen CJ, Hauser RA, et al. Caffeine and progression of Parkinson disease. Clin Neuropharmacol 2008;31:189–196.PubMedCrossRef Simon DK, Swearingen CJ, Hauser RA, et al. Caffeine and progression of Parkinson disease. Clin Neuropharmacol 2008;31:189–196.PubMedCrossRef
Metadata
Title
Neuroprotective and Anti-inflammatory Properties of a Coffee Component in the MPTP Model of Parkinson’s Disease
Authors
Kang-Woo Lee
Joo-Young Im
Jong-Min Woo
Hilary Grosso
Yoon-Seong Kim
Ana Clara Cristovao
Patricia K. Sonsalla
David S. Schuster
Marla M. Jalbut
Jose R. Fernandez
Michael Voronkov
Eunsung Junn
Steven P. Braithwaite
Jeffry B. Stock
M. Maral Mouradian
Publication date
01-01-2013
Publisher
Springer-Verlag
Published in
Neurotherapeutics / Issue 1/2013
Print ISSN: 1933-7213
Electronic ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-012-0165-2

Other articles of this Issue 1/2013

Neurotherapeutics 1/2013 Go to the issue